Stock GHRS GH RESEARCH PLC
Add to a list
To use this feature you must be a member
Log inSign up

GH Research PLC Stock

Equities

GHRS

IE000GID8VI0

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
14.09 USD +4.14% Intraday chart for GH Research PLC +2.85% +142.93%
May. 03 GH Research PLC Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 01 JMP Securities Cuts Price Target on GH Research to $39 From $50, Maintains Market Outperform Rating MT

Financials (USD)

Sales 2024 * - Sales 2025 * - Capitalization 733M
Net income 2024 * -42M Net income 2025 * -72M EV / Sales 2024 * -
Net cash position 2024 * 237M Net cash position 2025 * 265M EV / Sales 2025 * -
P/E ratio 2024 *
-17.9 x
P/E ratio 2025 *
-12 x
Employees 49
Yield 2024 *
-
Yield 2025 *
-
Free-Float 59.61%
More Fundamentals * Assessed data

Chart GH Research PLC

Dynamic Chart

Latest news about GH Research PLC

GH Research PLC Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
JMP Securities Cuts Price Target on GH Research to $39 From $50, Maintains Market Outperform Rating MT
GH Research PLC Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Stifel Adjusts Price Target on GH Research to $18 From $25, Maintains Buy Rating MT
HC Wainwright Cuts GH Research's Price Target to $40 From $45, Maintains Buy Rating MT
GH Research PLC Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
GH Research PLC Provides Updates and Guidance on Its Clinical Development Program for GH001 in Treatment-Resistant Depression CI
GH Research PLC Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Gh Research plc Announces Accepted for Publication in Frontiers in Psychiatry CI
JMP Securities Adjusts Price Target on GH Research to $49 From $46, Maintains Market Outperform Rating MT
GH Research PLC Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
GH Research's 2022 Net Loss Widens; Reports Sufficient Funds to Operate Into 2026 MT
GH Research PLC Reports Earnings Results for the Full Year Ended December 31, 2022 CI
EF Hutton Initiates GH Research at Buy With $33 Price Target MT
GH Research Q3 Loss Narrows MT
More news

Analyst Recommendations on GH Research PLC

JMP Securities Cuts Price Target on GH Research to $39 From $50, Maintains Market Outperform Rating MT
Stifel Adjusts Price Target on GH Research to $18 From $25, Maintains Buy Rating MT
HC Wainwright Cuts GH Research's Price Target to $40 From $45, Maintains Buy Rating MT
JMP Securities Adjusts Price Target on GH Research to $49 From $46, Maintains Market Outperform Rating MT
EF Hutton Initiates GH Research at Buy With $33 Price Target MT
More recommendations

Press releases GH Research PLC

GH Research : Notice of Annual General Meeting to be held on 27 June 2024 - Form 6-K PU
GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates AQ
GH Research Reports Full Year 2023 Financial Results and Provides Business Updates AQ
GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression AQ
GH Research Reports Third Quarter Financial Results and Provides Business Updates AQ
More press releases

Quotes and Performance

1 day+4.14%
1 week+2.85%
1 month+28.56%
3 months+58.67%
6 months+125.80%
Current year+142.93%
More quotes

Highs and lows

1 week
12.93
Extreme 12.93
14.53
1 month
11.19
Extreme 11.19
14.53
Current year
5.12
Extreme 5.12
14.53
1 year
5.05
Extreme 5.05
14.64
3 years
5.05
Extreme 5.05
30.43
5 years
5.05
Extreme 5.05
30.43
10 years
5.05
Extreme 5.05
30.43
More quotes

Managers and Directors - GH Research PLC

Managers TitleAgeSince
Magnus Halle FOU
 Founder 27 17-12-31
Theis Terwey CEO
 Chief Executive Officer 48 17-12-31
Julie Ryan DFI
 Director of Finance/CFO 38 20-12-31
Members of the board TitleAgeSince
Duncan Moore BRD
 Director/Board Member 65 21-09-23
Florian Schönharting FOU
 Founder 55 17-12-31
Michael Forer BRD
 Director/Board Member 58 20-11-30
More insiders

Quotes

Date Price Change Volume
24-05-31 14.09 +4.14% 53,872
24-05-30 13.53 +4.64% 27,209
24-05-29 12.93 -9.83% 47,144
24-05-28 14.34 +4.67% 46,975
24-05-24 13.7 +2.78% 37,519

Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT

More quotes

Company Profile

GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Sector
Biotechnology & Medical Research
Calendar
2024-08-20 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
14.09 USD
Average target price
32 USD
Spread / Average Target
+127.11%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
GH RESEARCH PLC Stock GH Research PLC
+142.93% 733M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+11.91% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.60% 106B
BIONTECH SE Stock BioNTech SE
-4.68% 24.28B
ARGENX SE Stock argenx SE
-0.82% 21.96B
GENMAB A/S Stock Genmab A/S
-10.12% 18.16B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.12% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.47% 15.56B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.77% 13.63B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.58% 12.27B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. GHRS Stock